Yes, Xeljanz (tofacitinib) is FDA-approved for treating moderately to severely active ulcerative colitis in adults who have had an inadequate response, loss of response, or intolerance to TNF blockers.[1][2]
How does Xeljanz work for ulcerative colitis?
Xeljanz is a Janus kinase (JAK) inhibitor that blocks enzymes involved in inflammation. For ulcerative colitis, it's taken as 10 mg twice daily for induction (8 weeks, extendable to 16 weeks) then 5 mg twice daily for maintenance in patients achieving clinical response.[1][3]
When was it approved for this use?
The FDA approved Xeljanz for ulcerative colitis in December 2019 as an oral treatment, marking it as the first JAK inhibitor for this condition. It's also approved in the EU and other regions.[1][2]
Who qualifies for Xeljanz treatment?
Eligible patients are adults with moderate to severe disease unresponsive to conventional therapies or biologics like TNF inhibitors. It's not for mild cases or as first-line therapy.[1][3]
What about common side effects in ulcerative colitis patients?
Frequent side effects include upper respiratory infections, headache, diarrhea, and nasal congestion. Serious risks involve infections (e.g., herpes zoster), blood clots, heart events, cancers, and gastrointestinal tears—black box warnings apply. Patients over 50 with heart risk factors face higher dangers.[1][2][3]
How does it compare to other ulcerative colitis drugs?
Unlike biologics such as Humira (adalimumab) or Stelara (ustekinumab), which are injectables targeting specific cytokines, Xeljanz is oral and works broadly on JAK pathways. Studies show similar remission rates to vedolizumab (Entyvio) but with faster onset; however, infection risks may be higher.[3]
Are there patent concerns or generics coming?
Xeljanz's main patents expire around 2025-2030, with extensions possible via pediatric exclusivity. Challenges from generics like those from MSN and Micro Labs are ongoing. Check DrugPatentWatch.com for litigation updates and exact expiry dates.[4]
[1]: FDA Label - Xeljanz (tofacitinib). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203214s022lbl.pdf
[2]: Pfizer Prescribing Information. https://labeling.pfizer.com/showlabeling.aspx?id=17271
[3]: OCTAVE Trials (NEJM 2017;377:644-657). https://www.nejm.org/doi/full/10.1056/NEJMoa1609217
[4]: DrugPatentWatch.com - Xeljanz Patents. https://www.drugpatentwatch.com/p/tradename/XELJANZ